What this means
This is a planned early study that will check whether a stem cell treatment is safe for older adults with mild to moderate frailty. It has not started enrolling people, and no results have been posted yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 60–85
- Where
- Not listed
The science
- Registered title
- Safety and Tolerability Study of Mesenchymal Stem Cells, HeXell-2020, in Elderly Subjects With Mild to Moderate Frailty Syndrome
- Trial ID
- NCT07144072 ↗
- Phase
- PHASE 1
- Study type
- interventional
- Conditions
- Frailty in Older Adults
- What is tested
- HeXell-2020
- Sponsor
- Hexun Biosciences Co., LTD.
- Ages
- 60 Years to 85 Years
- Dates
- First posted Aug 27, 2025 · updated Sep 25, 2026
Registry summary
This is a phase I study to investigate the safety, and Tolerability of HeXell-2020 in Elderly Subjects with Mild to Moderate Frailty Syndrome.
HeXell-2020 is an investigational drug product consisting of allogenic umbilical cord mesenchymal stem cells (UCMSCs) as the drug substance. All enrolled and eligible subjects will receive HeXell-2020 treatment.